Holen Sie sich die Stockscreener-App
1.54
4.94%
-0.08
Handel nachbörslich:
1.55
0.01
+0.65%
Schlusskurs vom Vortag:
$1.62
Offen:
$1.6
24-Stunden-Volumen:
1.02M
Relative Volume:
1.49
Marktkapitalisierung:
$111.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.3392
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
-0.65%
1M Leistung:
+3.36%
6M Leistung:
+26.23%
1J Leistung:
-47.97%
1-Tages-Spanne:
$1.53
$1.63
1-Wochen-Bereich:
$1.53
$1.84
52-Wochen-Spanne:
$1.01
$4.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Vergleichen Sie ZNTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.54 | 116.86M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Will Zentalis Pharmaceuticals Inc. stock keep outperforming rivalsDip Buying & Fast Gain Stock Tips - newser.com
How Zentalis Pharmaceuticals Inc. stock benefits from strong dollarPortfolio Return Report & Fast Momentum Stock Entry Tips - newser.com
Volatility clustering patterns for Zentalis Pharmaceuticals Inc.July 2025 Decliners & Real-Time Market Sentiment Alerts - newser.com
Zentalis to present azenosertib data at cancer therapeutics conference - Investing.com India
Zentalis Pharmaceuticals Announces Acceptance of Azenosertib Abstracts for Presentation at AACR-NCI-EORTC Conference - Quiver Quantitative
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Stock Titan
How currency fluctuations impact Zentalis Pharmaceuticals Inc. stockWall Street Watch & Risk Managed Investment Signals - newser.com
Can Zentalis Pharmaceuticals Inc. stock reach $100 price targetQuarterly Performance Summary & Technical Pattern Based Signals - newser.com
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress - ADVFN Ltd
Can Zentalis Pharmaceuticals Inc. hit a new high this monthTrade Risk Summary & Weekly High Potential Stock Alerts - newser.com
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Wealth Enhancement Advisory Services LLC - Defense World
What institutional flow reveals about Zentalis Pharmaceuticals Inc.Market Sentiment Review & Community Trade Idea Sharing - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
What earnings revisions data tells us about Zentalis Pharmaceuticals Inc.Weekly Trade Report & Entry Point Confirmation Alerts - newser.com
Full technical analysis of Zentalis Pharmaceuticals Inc. stockJuly 2025 Review & AI Optimized Trade Strategies - newser.com
Using data filters to optimize entry into Zentalis Pharmaceuticals Inc.Watch List & Verified Technical Trade Signals - newser.com
Zentalis Pharmaceuticals' (ZNTL) "Sell (E+)" Rating Reiterated at Weiss Ratings - MarketBeat
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Yahoo Finance
Key metrics from Zentalis Pharmaceuticals Inc.’s quarterly dataQuarterly Market Summary & Stepwise Swing Trade Plans - newser.com
Short interest data insights for Zentalis Pharmaceuticals Inc.2025 Fundamental Recap & Verified Short-Term Plans - newser.com
Pattern recognition hints at Zentalis Pharmaceuticals Inc. upsideJuly 2025 Review & Target Return Focused Picks - newser.com
How to build a dashboard for Zentalis Pharmaceuticals Inc. stockMarket Activity Report & Smart Swing Trading Techniques - newser.com
Positive week for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional investors who lost 48% over the past year - simplywall.st
What analysts say about Zentalis Pharmaceuticals Inc stockDebt-to-Equity Ratio Analysis & Ride the Trends That Billionaires Follow - earlytimes.in
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
400,000 Stock Options at $1.54: Zentalis Pharmaceuticals Welcomes New Chief Legal Officer with Major Grant - Stock Titan
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zentalis Pharmaceuticals Inc-Aktie (ZNTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):